Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Expanded Access to Tenofovir

October 9, 2001

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Tenofovir, also known as Viread, is a type of anti-HIV drug called a nucleotide reverse transcriptase inhibitor. Tenofovir is not a major breakthough -- it is not as potent as, say, the protease inhibitor indinavir (Crixivan). However, the advantage with tenofovir is that it only has to be taken once a day. Tenofovir will likely be approved for use only in people who have previously used anti-HIV medications. Until then, the manufacturer, Gilead Sciences, is making tenofovir available at no cost for physicians to give to some people with HIV/AIDS in the following countries:
  • Canada
  • United States
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
Gilead will consider requests for tenofovir from physicians in Canada for their patients with the following profile:
  • At least 18 years old
  • Viral load: at least 10,000 copies (Amplicor)
  • CD4+ count: 100 or fewer cells, OR 100-200 cells if an opportunistic infection has occurred in the past 90 days
  • Previous failure of at least two protease inhibitors, OR failure of one protease inhibitor and one non-nuke
For more information about the tenofovir expanded access program or to register patients in Canada and the U.S., physicians can phone: 1.877.226.8802. Physicians in Europe can call this number: 33.1.44.90.34.46.

Registration materials can be requested online by visiting the Gilead website at: http://www.gilead.com/webpage_templates/frame_home.php3.

A CATIE fact sheet about tenofovir is under development and will be available shortly.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Canadian AIDS Treatment Information Exchange. Visit CATIE's Web site to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on Tenofovir (Viread)

Tools
 

Advertisement